| Jefferson Hills Healthcare And Rehabilitation Cent | |
| 448 Old Clairton Road, Clairton, Pennsylvania 15025 | |
| (412) 653-1128 | |
| Name | Jefferson Hills Healthcare And Rehabilitation Cent |
|---|---|
| Location | 448 Old Clairton Road, Clairton, Pennsylvania |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 83 |
| Occupancy Rate | 93.86% |
| Medicare ID (CCN) | 395066 |
| Legal Business Name | Jefferson Hills Manor Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1467400960 |
| Organization Name | JEFFERSON HILLS MANOR LLC |
| Doing Business As | JEFFERSON HILLS HEALTHCARE AND REHABILITATION CENTER |
| Address | 448 Old Clairton Rd, Jefferson Hills, PA 15025 |
| Phone Number | 412-653-1128 |
News Archive
Study suggests our media and cultural obsession with achieving a certain weight does little to convince couch potatoes of any size to abandon their favorite sofa cushions and get active.
A scientist from the Florida campus of The Scripps Research Institute has been awarded just over $1 million from the National Institutes of Health to develop a range of new tests that could lead to new treatments for a number of stress-associated and degenerative disorders of advancing age.
Bristol-Myers Squibb Canada is pleased to announce that the Ontario government has made ERBITUX(TM) (cetuximab) available to patients suffering from metastatic colorectal cancer. This decision makes Ontario the second province, after British Columbia, to introduce funding for this important treatment option and represents encouraging news for those patients who rely on provincial drug coverage and stopped responding to standard treatments for metastatic colon cancer.
A clear association between obesity and pain - with higher rates of pain identified in the heaviest individuals - was found in a study of more than one million Americans published January 19 in the online edition of Obesity.
Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for the first time today at the Lysosomal Disease Network WORLD Symposium in Miami, Fla.
› Verified 1 days ago
| NPI Number | 1790423994 |
| Organization Name | JEFFERSON HILLS OPERATING LLC |
| Doing Business As | JEFFERSON HILLS HEALTHCARE AND REHABILITATION CENTER |
| Address | 448 Old Clairton Rd, Clairton, PA 15025 |
| Phone Number | 412-653-1128 |
News Archive
Study suggests our media and cultural obsession with achieving a certain weight does little to convince couch potatoes of any size to abandon their favorite sofa cushions and get active.
A scientist from the Florida campus of The Scripps Research Institute has been awarded just over $1 million from the National Institutes of Health to develop a range of new tests that could lead to new treatments for a number of stress-associated and degenerative disorders of advancing age.
Bristol-Myers Squibb Canada is pleased to announce that the Ontario government has made ERBITUX(TM) (cetuximab) available to patients suffering from metastatic colorectal cancer. This decision makes Ontario the second province, after British Columbia, to introduce funding for this important treatment option and represents encouraging news for those patients who rely on provincial drug coverage and stopped responding to standard treatments for metastatic colon cancer.
A clear association between obesity and pain - with higher rates of pain identified in the heaviest individuals - was found in a study of more than one million Americans published January 19 in the online edition of Obesity.
Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for the first time today at the Lysosomal Disease Network WORLD Symposium in Miami, Fla.
› Verified 1 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Study suggests our media and cultural obsession with achieving a certain weight does little to convince couch potatoes of any size to abandon their favorite sofa cushions and get active.
A scientist from the Florida campus of The Scripps Research Institute has been awarded just over $1 million from the National Institutes of Health to develop a range of new tests that could lead to new treatments for a number of stress-associated and degenerative disorders of advancing age.
Bristol-Myers Squibb Canada is pleased to announce that the Ontario government has made ERBITUX(TM) (cetuximab) available to patients suffering from metastatic colorectal cancer. This decision makes Ontario the second province, after British Columbia, to introduce funding for this important treatment option and represents encouraging news for those patients who rely on provincial drug coverage and stopped responding to standard treatments for metastatic colon cancer.
A clear association between obesity and pain - with higher rates of pain identified in the heaviest individuals - was found in a study of more than one million Americans published January 19 in the online edition of Obesity.
Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for the first time today at the Lysosomal Disease Network WORLD Symposium in Miami, Fla.
› Verified 1 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 13.89 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 5.94 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 44.88 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.36 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.81 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.9 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.59 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 89.64 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 10.26 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 85.03 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.46 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 26.4 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 13.33 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 5.88 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 95.45 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 60.4 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 90.21 | 82.93 |
News Archive
Study suggests our media and cultural obsession with achieving a certain weight does little to convince couch potatoes of any size to abandon their favorite sofa cushions and get active.
A scientist from the Florida campus of The Scripps Research Institute has been awarded just over $1 million from the National Institutes of Health to develop a range of new tests that could lead to new treatments for a number of stress-associated and degenerative disorders of advancing age.
Bristol-Myers Squibb Canada is pleased to announce that the Ontario government has made ERBITUX(TM) (cetuximab) available to patients suffering from metastatic colorectal cancer. This decision makes Ontario the second province, after British Columbia, to introduce funding for this important treatment option and represents encouraging news for those patients who rely on provincial drug coverage and stopped responding to standard treatments for metastatic colon cancer.
A clear association between obesity and pain - with higher rates of pain identified in the heaviest individuals - was found in a study of more than one million Americans published January 19 in the online edition of Obesity.
Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for the first time today at the Lysosomal Disease Network WORLD Symposium in Miami, Fla.
› Verified 1 days ago
Jefferson Hills Healthcare And Rehabilitation Cent Location: 448 Old Clairton Road, Clairton, Pennsylvania 15025 Phone: (412) 653-1128 |